Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer Establishes $400M Loan Facility for Caliper Purchase

NEW YORK (GenomeWeb News) – PerkinElmer has entered into a commitment letter for a 364-day bridge loan facility for up to $400 million to fund its proposed purchase of Caliper Life Sciences, it disclosed this week in a document filed with the US Securities and Exchange Commission.

The firm said it entered into a commitment letter on Sept. 7 with Bank of America and Merrill Lynch, Pierce, Fenner & Smith for the loan facility. Bank of America will act as an initial lender and administrative agent, while Merrill Lynch will be the lead arranger and book-running manager.

In addition to helping fund PerkinElmer's $600 million proposed acquisition of Caliper, the loan facility will be used to refinance certain of both firms' debt, and to pay fees and expenses incurred in connection with the transactions.

In connection with the loan facility, PerkinElmer has agreed to engage an investment banker and "use commercially reasonable efforts" to issue up to $400 million of senior unsecured notes or other securities.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.